PCSK9 Inhibitor Market Report 2026

The pcsk9 inhibitor market size has grown exponentially in recent years. It will grow from $3.24 billion in 2025 to $3.92 billion in 2026 at a compound annual growth rate (CAGR) of 21%. The growth in the historic period can be attributed to limited availability of pcsk9 inhibitors, reliance on monoclonal antibody therapies, growing awareness of cardiovascular disease risks, increasing physician prescriptions of lipid-lowering drugs, regulatory approvals for first-generation pcsk9 inhibitors.

The pcsk9 inhibitor market size is expected to see exponential growth in the next few years. It will grow to $8.28 billion in 2030 at a compound annual growth rate (CAGR) of 20.6%. The growth in the forecast period can be attributed to launch of inclisiran and other siRNA therapies, expansion of combination therapy options, increasing adoption of personalized medicine approaches, rising healthcare expenditure on cardiovascular disease management, development of digital patient monitoring and adherence programs. Major trends in the forecast period include rising prevalence of hypercholesterolemia and cardiovascular diseases, increased adoption of subcutaneous and intravenous administration routes, development of biosimilars and combination therapies, growing investment in personalized lipid-lowering treatments, expansion of specialty clinics and hospital-based pcsk9 therapy programs.

The rising prevalence of hyperlipidemia is expected to drive growth in the PCSK9 inhibitor market in the coming years. Hyperlipidemia is a condition marked by elevated levels of lipids, including cholesterol and triglycerides, in the bloodstream, increasing the risk of cardiovascular diseases. Its prevalence is growing due to aging populations, as cholesterol levels typically rise significantly after age 45. PCSK9 inhibitors help manage hyperlipidemia by enhancing the liver’s ability to remove excess LDL cholesterol from the blood, improving overall lipid profiles. For example, in December 2023, the Australian Bureau of Statistics reported that high cholesterol rates increase sharply from 1.1% among individuals aged 18-34 to 29% in those aged 75 and older. Therefore, the rising prevalence of hyperlipidemia is propelling growth in the PCSK9 inhibitor market.

Key companies in the PCSK9 inhibitor market are focusing on innovative solutions such as in vivo gene therapy to provide long-lasting or one-time treatments that permanently lower LDL cholesterol in high-risk cardiovascular patients. In vivo gene therapy involves delivering genetic material directly into the patient’s body to modify or replace defective genes in targeted cells, producing therapeutic effects at the source of disease. For instance, in April 2025, Verve Therapeutics Inc., a US-based clinical-stage company, reported early results from its Heart-2 Phase 1b trial of VERVE-102, targeting patients with heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease. A single dose of VERVE-102 led to dose-dependent reductions in PCSK9 protein and LDL-C levels, with the 0.6 mg/kg group experiencing an average LDL cholesterol drop of 53% and some participants reaching a maximum reduction of 69%, highlighting its potential as a powerful cholesterol-lowering therapy.

In March 2024, LIB Therapeutics, a US-based biopharmaceutical company, partnered with Hasten Biopharmaceuticals to commercialize its PCSK9 inhibitor LIB003 in China. Through this partnership, LIB Therapeutics aims to accelerate the clinical development and regulatory approval of lerodalcibep in China by leveraging Hasten Biopharmaceuticals’ expertise in the country’s regulatory landscape and market dynamics, advancing a novel therapeutic option for patients with hypercholesterolemia. Hasten Biopharmaceuticals Co., Ltd. is a China-based company specializing in clinical development and drug manufacturing, supporting the clinical trial application for lerodalcibep.

Major companies operating in the pcsk9 inhibitor market are Sanofi S.A, Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Innovent Biologics Inc., Shanghai Junshi Biosciences Co. Ltd., Akeso Inc., Verve Therapeutics Inc., LIB Therapeutics LLC, Vaxxinity Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Shenyang Xinlitai Pharmaceutical Co. Ltd.

North America was the largest region in the PCSK9 inhibitor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pcsk9 inhibitor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pcsk9 inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the PCSK9 inhibitor market by increasing costs of imported raw materials, biologics, and active pharmaceutical ingredients used in monoclonal antibodies and siRNA therapies. Segments like fully-humanized monoclonal antibodies and small interfering RNA (siRNA) therapies are most impacted, particularly in North America and Asia-Pacific regions including China and India. This has led to higher treatment costs and potential delays in drug availability. On the positive side, tariffs have encouraged domestic manufacturing, investment in local R&D, and innovation in cost-effective PCSK9 therapies.

The pcsk9 inhibitor market research report is one of a series of new reports that provides pcsk9 inhibitor market statistics, including pcsk9 inhibitor industry global market size, regional shares, competitors with a pcsk9 inhibitor market share, detailed pcsk9 inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the pcsk9 inhibitor industry. This pcsk9 inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

PCSK9 inhibitors are medications that lower LDL cholesterol by preventing the PCSK9 protein from degrading LDL receptors on liver cells. By blocking PCSK9, these inhibitors enhance the liver’s capacity to remove low-density lipoprotein cholesterol, thereby reducing blood cholesterol levels and lowering the risk of cardiovascular diseases.

The main drug types of PCSK9 inhibitors include alirocumab, evolocumab, inclisiran, bococizumab, and others. Alirocumab is a fully human monoclonal antibody that inhibits PCSK9 to reduce LDL cholesterol levels in patients with hypercholesterolemia. These drugs can be administered orally, subcutaneously, or intravenously, and the modalities include fully human monoclonal antibodies and small interfering RNA (siRNA). They are applied in conditions such as hypercholesterolemia, hyperlipidemia, cardiovascular disease prevention, and familial hypercholesterolemia, and are distributed through hospitals, specialty clinics, retail pharmacies, and online pharmacies.

The PCSK9 inhibitor market consists of sales of monoclonal antibodies, sirna therapies, small molecule inhibitors, and peptide-based inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.